Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
06:47pm, Tuesday, 22'nd Aug 2023
The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Thursday, 10'th Aug 2023
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.87 per share a year ago.
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
08:05am, Thursday, 03'rd Aug 2023
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trial
03:42pm, Monday, 31'st Jul 2023
Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the United States Food and Drug Administration (FDA) f
Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK
03:06pm, Wednesday, 05'th Jul 2023
Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other ass
Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript
08:59pm, Thursday, 11'th May 2023
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mah
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.01 per share a year ago.
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
08:05am, Thursday, 04'th May 2023
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializ
Spero Therapeutics to Present at Upcoming Investor Conference
08:05am, Wednesday, 26'th Apr 2023
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and co
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market
04:46pm, Friday, 21'st Apr 2023
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market.
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
08:05am, Friday, 14'th Apr 2023
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercial
Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript
10:11pm, Thursday, 30'th Mar 2023
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Ted Jenkins - VP & Head, IR Ankit Mahadevia - Co-Founder, President, CEO & Direc
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat Estimates
07:11pm, Thursday, 30'th Mar 2023
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 237.50% and 2,865.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023
08:05am, Monday, 13'th Mar 2023
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercial
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercial
